No Data
2024 Annual Results Forecast
Kexing Biopharm (688136.SH): The expected Net income for 2024 is around 30 million yuan.
On January 17, Glonghui reported that Kexing Biopharm (688136.SH) announced its annual performance forecast for 2024. According to preliminary calculations by the financial department, it is expected that the net income attributable to the owners of the parent company will turn from loss to profit compared to the same period last year (statutory disclosure data), with the net income attributable to the owners of the parent company estimated to be around 30 million yuan. The net income attributable to the owners of the parent company, excluding non-recurring gains and losses, is estimated to be around 33 million yuan.
On December 30th, A-share investment shields︱Kangxi Communication: Shareholder Yancheng Semiconductors and Gongqingcheng Kangsheng plan to reduce their Shareholding by no more than 3%.
Shareholders of Zhejiang Shengda Bio-Pharm, Wanjian Investment, plan to reduce their shareholding by no more than 3%; multiple shareholders of Montage Technology plan to collectively reduce their shareholding by no more than 2%; South Chip Technology has cumulatively reduced its shareholding by 1% in Shanghai; shareholders of Kangxi Communication, Yancheng Semiconductors and Gongqingcheng Kangsheng, plan to reduce their shareholding by no more than 3%; Jiangsu Zhongshe Group has terminated its plan for a significant asset restructuring; First Tractor has terminated its significant asset sale; Kexing Biopharm has terminated the clinical trial of its interferon α2b spray.
Kexing Biopharm (688136.SH) has newly designated Li Huiming and Shang Wei as key technical personnel.
Kexing Biopharm (688136.SH) announced that the company's original core technical staff member, Mr. He Shehui, will no longer participate in the company's specific...
Kexing Biopharm (688136.SH): Using some idle raised funds and self-owned funds for Cash / Money Market management.
Gelonghui reported on December 27 that Kexing Biopharm (688136.SH) announced that, on the premise of not affecting the normal implementation of the company's fundraising investment projects (referred to as "fundraising projects") and ensuring the safety of the raised funds, it will use a maximum balance of no more than 0.2 billion yuan (including 0.2 billion) of idle raised funds and a maximum balance of no more than 0.3 billion yuan (including 0.3 billion yuan) of its own funds for cash management.
Kexing Biopharm (688136.SH): Regarding the termination of the clinical trial for interferon α2b spray.
On December 27, Gelonghui reported that Kexing Biopharm (688136.SH) announced that its developed human interferon α2b spray is in the clinical research phase. Recently, after careful consideration of the subsequent development risks of the drug, the company decided to terminate the clinical trial for this project.
Revenues Working Against Shandong Kexing Bioproducts Co,.Ltd's (SHSE:688136) Share Price Following 26% Dive